Setmelanotide clinical trials: 15 trials
Page 1 of 1
Read 15 Setmelanotide clinical trials with posted results or linked papers with results in PepBank.
- Long Term Extension Trial of Setmelanotide
NCT03651765 · Phase 2/3 · Completed
Posted results
- A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756 · Phase 3 · Active, not recruiting
Posted results
- Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
NCT05046132 · Phase 4 · Completed
Posted results
- Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
NCT03746522 · Phase 3 · Completed
Posted results
- Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
NCT05194124 · Phase 3 · Completed
Posted results
- Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
NCT02896192 · Phase 3 · Completed
Posted results
- Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity
NCT03287960 · Phase 3 · Completed
Posted results
- Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
NCT04966741 · Phase 3 · Completed
Posted results
- Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity
NCT07674290 · Phase 4 · Recruiting
Linked paper with results
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
NCT03013543 · Phase 2 · Completed
Posted results
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
NCT04963231 · Phase 2 · Completed
Posted results
- Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients
NCT02041195 · Phase 1/2 · Completed
Posted results
- Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
NCT01749137 · Phase 2 · Completed
Posted results
- Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
NCT02311673 · Phase 2 · Completed
Posted results
- Open-Label Study of Setmelanotide in Hypothalamic Obesity
NCT04725240 · Phase 2 · Completed
Posted results